Therapeutic gene editing in haematological disorders with CRISPR/Cas9

  title={Therapeutic gene editing in haematological disorders with CRISPR/Cas9},
  author={Trine I Jensen and Esben Axelgaard and Rasmus O. Bak},
  journal={British Journal of Haematology},
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR‐associated (Cas)9 platform offers an efficient way of making precise genetic changes to the human genome. This can be employed for disruption, addition and correction of genes, thereby enabling a new class of genetic therapies that can be applied to haematological disorders. Here we review recent technological advances in the CRISPR/Cas9 methodology and applications in haematology for curing monogenic genetic… 

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

The applications and explorations of CRISPR/Cas9 technology in constructing allogenic universal CAR T cells are reviewed, disrupting inhibitory signaling to enhance potency and exploration of safer and more controllable novel CAR T Cells are reviewed.

CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome

The findings encourage the pursuit of CRISPR/Cas-based gene editing approaches, which may constitute more precise, affordable, and low-risk definitive treatment options for DOCK8 deficiency.

Advances in gene therapy for hematologic disease and considerations for transfusion medicine.

The milestones in the development of gene therapies for hematologic diseases, mechanisms for gene manipulation, and implications for transfusion medicine and blood centers as these therapies continue to advance and grow are summarized.

Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy

Cutting-edge available strategies for in vivo delivery of genome-editing technologies for HPV-induced cervical cancer therapy, including the combination of nanoparticle-based delivery systems and genome-EDiting tools are discussed.

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD

The development of antigen-specific cell-based immunotherapies for autoimmune diseases is slowed down by the rarity of the diseases, the lack of surrogate outcomes and biomarkers that are able to predict long-term outcomes and/or therapy effectiveness as well as challenges in the manufacturing of cellular products.

Novel genetic therapeutic approaches for modulating the severity of β-thalassemia (Review)

Gene therapy using the lentiglobin vector is the most recent method for cure without any mortality, graft rejection and clonal dominance issues, however, delayed platelet engraftment is being reported in some patients.

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.

This treatment has achieved long-term and curative therapeutic efficacy in multiple blood malignancies that nowadays profoundly change the treatment landscape of lymphoma, leukemia, and multiple myeloma, but CART-cell therapy is associated with several hurdles, such as limited therapeutic efficacy, little effect on solid tumors, adverse effects, expensive cost, and feasibility issues, hindering its broader implications.

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies

The EHA scientific working group for immunotherapy has defined major research questions for the future development of immunotherapy for patients with hematological malignancies.

Customized immunology for precision medicine

  • M. SchönT. Buhl
  • Biology, Medicine
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • 2021
The rapid developments in immunology are particularly important and interesting for us dermatologists, because they teach us more and more about pathophysiological processes as well as targeted therapies with fewer side effects.



Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA Repair

A modified version of Cas9 with reduced nuclease activity in G1 phase of cell cycle when HDR cannot occur is used, and transiently increasing the proportion of cells in HDR‐preferred phases (S/G2) achieves a four‐fold improvement in HDR/NHEJ ratio over the control condition in vitro.

Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9.

This review will outline the recent development of genome-editing technology, culminating with the use of CRISPR-Cas9 to generate novel mammalian models of disease.

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

This work describes a method to multiplex homologous recombination in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs).

Fanconi anemia gene editing by the CRISPR/Cas9 system.

It is shown that the Cas9 nuclease and nickase each resulted in gene correction, but the nickase, because of its ability to preferentially mediate homology-directed repair, resulted in a higher frequency of corrected clonal isolates.

CRISPR–Cas9 genome editing in human cells occurs via the Fanconi anemia pathway

It is found that human Cas9-induced SSTR requires the Fanconi anemia pathway, which is normally implicated in interstrand cross-link repair, and this implies that patient genotype and/or transcriptome may impact the effectiveness of gene editing treatments and that treatments biased toward FA repair pathways could have therapeutic value.

Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs

A comparison of using TALens or CRISPR/Cas9 to correct specific HBB mutations in patient-derived iPSCs will guide future applications of TALENs- or CRisPR/ Cas9-based gene therapies in monogenic diseases.

CRISPR/Cas9 genome editing in human hematopoietic stem cells.

This protocol enables manipulation of genes for investigation of gene functions during hematopoiesis, as well as for the correction of genetic mutations in HSC transplantation-based therapies for diseases such as sickle cell disease, β-thalassemia, and primary immunodeficiencies.

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

The results demonstrate correction of the sickle mutation in patient-derived CD34+ cells using CRISPR/Cas9 technology, leading to the production of wild-type hemoglobin.

CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

These preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.

Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells

Gene-edited HSCs sustained normal haematopoiesis and gave rise to functional lymphoid cells that possess a selective growth advantage over those carrying disruptive IL2RG mutations, which opens up new avenues for treating SCID-X1 and other diseases.